Zygulska AL, Pierzchalski P. Novel diagnostic biomarkers in colorectal cancer. Int J Mol Sci. 2022;23(2):852. https://doi.org/10.3390/ijms23020852.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022;72(4):372–401. https://doi.org/10.3322/caac.21728.

Article  PubMed  Google Scholar 

National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: colorectal cancer https://seer.cancer.gov/statfacts/html/colorect.html

Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–85. https://doi.org/10.1001/jama.2021.0106.

Article  CAS  PubMed  Google Scholar 

Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10–32. https://doi.org/10.1016/j.annonc.2022.10.003.

Article  CAS  PubMed  Google Scholar 

Lastraioli E, Bettiol A, Iorio J, Limatola E, Checcacci D, Parisi E, et al. Evaluation of RAS mutational status in liquid biopsy to monitor disease progression in metastatic colorectal cancer patients. Cells. 2023;12(11):1458. https://doi.org/10.3390/cells12111458.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsai HL, Lin CC, Sung YC, Chen SH, Chen LT, Jiang JK, et al. The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study. Br J Cancer. 2023;129(6):947–55. https://doi.org/10.1038/s41416-023-02366-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cremolini C, Montagut C, Ronga P, Venturini F, Yamaguchi K, Stintzing S, et al. Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer. Front Oncol. 2023;12:946850. https://doi.org/10.3389/fonc.2022.946850.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martini G, Ciardiello D, Famiglietti V, Rossini D, Antoniotti C, Troiani T, et al. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: individual patient data pooled analysis of CRICKET and CAVE trials. Cancer Med. 2023;12(8):9392–400. https://doi.org/10.1002/cam4.5699.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mauri G, Pizzutilo EG, Amatu A, Bencardino K, Palmeri L, Bonazzina EF, et al. Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat Rev. 2019;73:41–53. https://doi.org/10.1016/j.ctrv.2018.12.006.

Article  CAS  PubMed  Google Scholar 

Ciardiello D, Martini G, Famiglietti V, Napolitano S, De Falco V, Troiani T, et al. Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer. Cancers (Basel). 2021;13(8):1941. https://doi.org/10.3390/cancers13081941.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2012;23(9):2313–8. https://doi.org/10.1093/annonc/mdr623.

Article  CAS  PubMed  Google Scholar 

Chong LC, Hardingham JE, Townsend AR, Piantadosi C, Rico GT, Karapetis C, et al. Rechallenge with anti-EGFR therapy in metastatic colorectal cancer (mCRC): results from South Australia mCRC registry. Target Oncol. 2020;15(6):751–7. https://doi.org/10.1007/s11523-020-00760-8.

Article  PubMed  Google Scholar 

Cremolini C, Rossini D, Dell’Aquila E, Lonardi S, Conca E, Del Re M, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019;5(3):343–50. https://doi.org/10.1001/jamaoncol.2018.5080.

Article  PubMed  Google Scholar 

Masuishi T, Tsuji A, Kotaka M, Nakamura M, Kochi M, Takagane A, et al. Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08. Br J Cancer. 2020;123(10):1490–5. https://doi.org/10.1038/s41416-020-01042-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sunakawa Y, Nakamura M, Ishizaki M, Kataoka M, Satake H, Kitazono M, et al. RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC). WCGC 2019.

Tsuji A, Nakamura M, Watanabe T, Manaka D, Matsuoka H, Kataoka M, et al. Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who obtained clinical benefit from first-line panitumumab-based chemotherapy: JACCRO CC-09. Target Oncol. 2021;16(6):753–60. https://doi.org/10.1007/s11523-021-00845-y.

Article  PubMed  Google Scholar 

Vassilev Z, Guo H, Lin W, Xu J, Khan N. Age-related trends in the incidence of metastatic colorectal cancer over the last 10 years: a retrospective analysis in commercially-insured population in the United States. J Clin Oncol. 2022;40(4_suppl):46–46.

Article  Google Scholar 

Medici B, Riccò B, Caffari E, Zaniboni S, Salati M, Spallanzani A, et al. Early onset metastatic colorectal cancer: current insights and clinical management of a rising condition. Cancers (Basel). 2023;15(13):3509. https://doi.org/10.3390/cancers15133509.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022;28(8):1612–8. https://doi.org/10.1038/s41591-022-01886-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martinelli E, Martini G, Famiglietti V, Troiani T, Napolitano S, Pietrantonio F, et al. Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial. JAMA Oncol. 2021;7(10):1529–35. https://doi.org/10.1001/jamaoncol.2021.2915.

Article  PubMed  Google Scholar 

Napolitano S, De Falco V, Martini G, Ciardiello D, Martinelli E, Della Corte CM, et al. Panitumumab plus trifluridine-tipiracil as anti-epidermal growth factor receptor rechallenge therapy for refractory RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2023;9(7):966–70. https://doi.org/10.1001/jamaoncol.2023.0655.

Article  PubMed  PubMed Central  Google Scholar 

Napolitano S, Ciardiello D, De Falco V, Martini G, Martinelli E, Della Corte CM, et al. Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: overall survival and subgroup analysis of the randomized phase II VELO trial. Int J Cancer. 2023;153(8):1520–8. https://doi.org/10.1002/ijc.34632.

Article  CAS  PubMed  Google Scholar 

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–45. https://doi.org/10.1056/NEJMoa033025.

Article  CAS  PubMed  Google Scholar 

Moretto R, Rossini D, Capone I, Boccaccino A, Perrone F, Tamborini E, et al. Rationale and study design of the PARERE trial: randomized phase II study of panitumumab re-treatment followed by regorafenib versus the reverse sequence in RAS and BRAF wild-type chemo-refractory metastatic colorectal cancer patients. Clin Colorect Cancer. 2021;20(4):314–7. https://doi.org/10.1016/j.clcc.2021.07.001.

Article  Google Scholar 

Strickler JH, Ou F-S, Bekaii-Saab TS, Parseghian CM, Cercek A, Ng K, et al. PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC). J Clin Oncol. 2021;39(3):TPS143-TPS. https://doi.org/10.1200/JCO.2021.39.3_suppl.TPS143.

Article  Google Scholar 

Metastatic Colorectal Cancer (RAS-wildtype) after response to first-line treatment with FOLFIR plus cetuximab (AIO-KRK-0114). ClinicalTrials.gov Identifier: NCT02934529

Napolitano S, Martini G, Ciardiello D, Di Maio M, Normanno N, Avallone A, et al. CAVE-2 (Cetuximab-AVElumab) mCRC: a phase ii randomized clinical study of the combination of avelumab plus cetuximab as a rechallenge strategy in pre-treated RAS/BRAF wild-type mCRC patients. Front Oncol. 2022;12: 940523. https://doi.org/10.3389/fonc.2022.940523.

Article  CAS  PubMed  PubMed Central  Google Scholar